Drug intelligence / Profile preview

SAR438544

Development stage: Discontinued
Lead developer: Sanofi
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

SAR438544 is a stable glucagon analog developed by Sanofi for the treatment of type 1 diabetes mellitus. It acts as an agonist of the glucagon receptor (GCGR), aiming to counteract hypoglycemia by stimulating hepatic glucose production. The drug was formulated for subcutaneous administration and underwent phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy subjects and patients with type 1 diabetes mellitus. Development was discontinued after phase 1 trials[2][3][5].

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on SAR438544.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR438544.

Explore the full profile